An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis

• Autors principals: Mohd. Imran (Autor), Shah Alam Khan (Autor), Syed Mohammed Basheeruddin Asdaq (Autor), Mazen Almehmadi (Autor), Osama Abdulaziz (Autor), Mehnaz Kamal (Autor), Mohammed Kanan Alshammari (Autor), Lojain Ibrahim Alsubaihi (Autor), Khansa Hamza Hussain (Autor), Abrar Saleh Alharbi (Autor), A. Khuzaim Alzahrani (Autor)
• Format: Llibre
• Publicat: Elsevier, 2022-10-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1) inhibitors are an innovative and futuristic orally active group of antituberculosis agents. A few DprE1 inhibitors are in the clinical trial for tuberculosis (TB), including macozinone. This review highlights the discovery, developmental status,...